Literature DB >> 11191832

Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons.

S Erhardt1, H Oberg, G Engberg.   

Abstract

Previous studies have shown that systemically administered nicotine is associated with an activation of rat midbrain dopamine neurons. The aim of the present electrophysiological study was to investigate if manipulation of brain kynurenic acid, an endogenous excitatory amino acid receptor antagonist, can affect the response of nigral dopamine neurons to nicotine. A potent inhibitor of kynurenine 3-hydroxylase, PNU 156561A (40 mg/kg, i.v., 4-7 h), was utilized to increase the levels of kynurenic acid in rat brain. This treatment, which caused a fourfold increase in brain kynurenic acid levels, abolished the increase in firing rate and burst activity of nigral dopamine neurons as induced by nicotine (25-400 microg/kg, i.v.). It is proposed that the excitation of dopamine neurons in the substantia nigra following nicotine administration is an indirect effect, mediated by glutamate release. In addition, our data highlight the role of brain kynurenic acid as a potentially important modulator of basic glutamatergic responses in brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11191832     DOI: 10.1007/s002100000325

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  10 in total

1.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

2.  Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

Authors:  H-Q Wu; A Rassoulpour; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

3.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

Review 4.  Endogenous neuro-protectants in ammonia toxicity in the central nervous system: facts and hypotheses.

Authors:  Jan Albrecht; Michał Wegrzynowicz
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

Review 5.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 6.  Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

Authors:  Robert Schwarcz; Paolo Guidetti; Korrapati V Sathyasaikumar; Paul J Muchowski
Journal:  Prog Neurobiol       Date:  2009-04-24       Impact factor: 11.685

7.  Apoptosis-mediated anticancer activity in prostate cancer cells of a chestnut honey (Castanea sativa L.) quinoline-pyrrolidine gamma-lactam alkaloid.

Authors:  Giangiacomo Beretta; Roberta Manuela Moretti; Rita Nasti; Raffaella Cincinelli; Sabrina Dallavalle; Marina Montagnani Marelli
Journal:  Amino Acids       Date:  2021-05-04       Impact factor: 3.520

8.  Kynurenine Pathway in Skin Cells: Implications for UV-Induced Skin Damage.

Authors:  Diba Sheipouri; Nady Braidy; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2012-07-03

Review 9.  Kynurenic Acid in the digestive system-new facts, new challenges.

Authors:  Michal P Turski; Monika Turska; Piotr Paluszkiewicz; Jolanta Parada-Turska; Gregory F Oxenkrug
Journal:  Int J Tryptophan Res       Date:  2013-09-04

Review 10.  Kynurenic acid and cancer: facts and controversies.

Authors:  Katarzyna Walczak; Artur Wnorowski; Waldemar A Turski; Tomasz Plech
Journal:  Cell Mol Life Sci       Date:  2019-10-28       Impact factor: 9.261

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.